Gallium Ga 68 gozetotide is composed of a human PSMA-targeting ligand peptide conjugated to the radioisotope Ga 68, a β+ emitting radionuclide that allows for PET imaging. It works by binding to ...

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) ...

The five-level PRIMARY system, which is based on a combination of 68 Ga-PSMA pattern, localization, and intensity information, was used to report prostate 68 Ga-PSMA PET/MRI findings. After ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for gastrointestinal and genitourinary cancers such as prostate-specific membrane antigen ...

The combination of these innovative technologies reflects Telix’s commitment to working in partnership to reach more patients with 68 Ga-PSMA-11, where and when they need it.” The QIS® forms ...

Specifically, once Gozellix is combined with 68 Ga, the now-FDA-approved imaging agent is used to detect PSMA positive lesions during PET scans in men with prostate cancer who have suspected ...

He remains symptom-free. The treatment is now approved for more patients. The randomized trial in 468 patients showed that 177 Lu-PSMA-617 prolonged progression-free survival (the period when the ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET[1] imaging agent Illuccix® ...

The FDA has approved Gozellix (kit for the preparation of gallium Ga 68 gozetotide injection), a radioactive diagnostic agent for prostate cancer detection.

The combination of these innovative technologies reflects Telix’s commitment to working in partnership to reach more patients with 68 Ga-PSMA-11, where and when they need it.” The QIS® forms part of ...